ClinicalTrials.gg
Active, not recruitingNCT07056322Updated Nov 4, 2026

Optimal Meals to Reduce Bone Resorption in Women With Osteopenia

An interventional study of 200 ml dairy and 100 ml milk in Osteopenia, sponsored by University of Aarhus. Active, not recruiting at 1 site in Denmark. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Aarhus · Not applicable, Interventional, and Prevention

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
Up to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Bone Diseases, Metabolic with a site in Denmark — 2 open to participants now, 5 under way, none of them phase 3. Bone Diseases, Metabolic · Denmark.

Planned enrollment
22nd of 23
13 · median 85
Started
2025
with 2 others
No phase
9 of 26
1 open now
Registered
25th of 26
by date
Lead sponsor
5 of 26
University of Aarhus

Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 25th registered.

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

2 of the 26 studies in Bone Diseases, Metabolic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: Up to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Bone Diseases, Metabolic with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether different types of small meals can help reduce bone loss in postmenopausal women with osteopenia, a condition where bone density is lower than normal and may lead to osteoporosis.

The main hypothesis is:

- A small amount of dairy (100 ml) is just as effective as a larger meal containing dairy and banana in reducing bone resorption.

Based on this, the study aims to answer the following questions:

- Which type and size of meal is most effective in reducing bone resorption?

Researchers will compare five different types of meals to a fasting control day to determine which meals best reduce markers of bone loss in the blood.

Participants will attend six clinical visits: five involving the intake of different test meals, and one control visit involving fasting. The participants will have blood samples taken over a period of 6 hours after each meal or fasting period to measure markers of bone metabolism.

This study aims to identify a simple, non-drug-based strategy to support bone health and help prevent progression to osteoporosis.

Read the detailed description

This project investigates whether administration of a meal can reduce bone resorption and thereby, if used strategic, prevent the development of osteoporosis in postmenopausal women with osteopenia, as measured by bone turnover markers and bone density. Furthermore, it is investigated which type and size of meal is optimal for bone health in osteopenia.

The project comprises of one hypotheses:

- 100 ml dairy is as effective as larger amounts of dairy and banana in decreasing bone resorption.

Osteopenia is a prevalent condition and is a precursor to osteoporosis and fractures. In 2011 it is estimated that osteoporotic fractures resulted a total cost of 1.6 billion EUR in Denmark. Osteopenia is diagnosed by a low bone mineral density (BMD), with a T-score between -1.1 and - 2.4, whereas osteoporosis is diagnosed by a T-score of ≤2.5. In postmenopausal women, it is estimated that 43 % have osteopenia. The current recommendation to prevent fractures in osteopenia is sufficient intake of vitamin D and calcium, besides smoking cessation, physical activity, and moderate alcohol intake. In case of osteoporosis, additional anti-osteoporotic medications are recommended, which have been shown to reduce fracture rates. However, effective non-pharmacologic remedies to prevent progression from osteopenia to osteoporosis are urgently needed and the potential of timing of meals in this context should therefore be explored. Osteopenia and osteoporosis are caused by an increased bone resorption to bone formation ratio which decreases BMD and increases fractures. During the bone resorption and bone formation phases; products are released to the bloodstream and can be measured as bone turnover markers. Carboxy-terminal collagen crosslinks (CTX) is a bone resorption marker and procollagen type I Npropeptide (P1NP) is a bone formation marker and they are internationally recommended as the standard bone turnover markers. Following a meal, bone resorption decreases. The gut hormone; glucagon-like peptide 2 (GLP-2) is released to the circulation following a meal and reduces bone resorption, as measured by CTX, by 50 %. In humans bone resorption is highly increased during the night time (fasting state) and gut hormones have therefore been suggested as treatments for osteoporosis. In a previous study, GLP-2 was administered subcutaneously before bedtime for 120 days and showed a decrease in nightly CTX levels and an increase in bone mineral density at the hip and no signs of tachyphylaxis during the treatment. The investigators have shown that a meal suppresses CTX levels for as long as six hours with a simultaneous increase in GLP-2 and that the oral administration of nutrients is essential for a reduction in CTX. The investigators have great experience in conducting clinical trials assessing bone health. In this project it is investigated which type and size of meals reduce CTX most profoundly.

The meals in this study are selected as 3.5 % fatty dairy or banana as these are commonly used smaller meals. Furthermore, the gastric emptying of a dairy depends on the meal size, and fat reduces the gastric emptying, whereas banana contains fibers and may thus have a shorter gastric emptying. Yoghurt is expected to have slower gastric emptying than milk primarily due to its higher viscosity. Additionally yoghurt is a more fermented product compared to milk, potentially affecting the postprandial gut hormone response differently. Psyllium and banana (pectin fibers) are both dietary fiber sources but differ in fiber composition and solubility, which may lead to different effects on gastric emptying and gut hormone responses. The fiber content differs between banana and psyllium, with psyllium being more concentrated. We aim to adjust the fiber content to be approximately equivalent, so participants will receive 4-5 g of psyllium (1 teaspoon), providing about the same amount of fiber as 100 g of banana.

The results from this study will be used for a follow up study in which the effects on bone health of meal administration over a longer period will be assessed.

03

Conditions studied

  • Osteopenia

Keywords

  • Osteopenia
  • Meal intervention
  • Bone turnover
04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteopenia at the lumbar spine defined as BMD t-score -2.4 to -1.1.
  • women
  • Age \< 80 years
  • CTX level ≥ 0.40 ng/ml
  • 17-25 kg/m2

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of osteoporosis, diabetes, primary hyperparathyroidism or active .
  • Current or recent (within two years) use of systemic for 4 continuous weeks or more, anticonvulsants or anti-osteoporotic drugs including systemic estrogen treatment.
  • Low p-25-OH vitamin D-levels (\< 50 pmol/l)
  • Estimated glomerular filtration () \<60 ml/min
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Meals or fasting in randomized order

    All participants will receive each of the six interventions (five different meals and one fasting control) in randomized order, with a minimum 1 week washout between test days. The order of the interventions is individually randomized. Blood samples will be collected at arrival and hourly during each visit to assess bone turnover markers.

    Dietary Supplement: 200 ml dairy · Dietary Supplement: 100 ml milk · Dietary Supplement: 100 g banana · Dietary Supplement: 100 ml dairy and fibers · Other: Fasting (control) · Dietary Supplement: 100 ml dairy

Interventions

  • Dietary supplement200 ml dairy

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

  • Dietary supplementcow's milkStudies of cow's milkcow's milk pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

  • Dietary supplementBananaStudies of BananaBanana pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

  • Dietary supplement100 ml dairy and fibers

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

  • OtherFasting (control)

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

  • Dietary supplement100 ml dairy

    Participants consume the meal after a fasting baseline bloodsample. Bloodsamples are collected over a six-hour period to evaluate postpandrial changes in bone turnover markers.

06

What researchers measure

Primary outcomes

  1. Bone resoroption

    The primary endpoint of the study is difference in the area under curve of the bone resorption marker CTX during the different study days

    Time frame: From enrollment through six study visits over a period of approximately 12 weeks

Secondary outcomes

  1. Change in bone formation marker P1NP

    Secondary outcome assesing changes in the bone formation marker P1NP

    Time frame: From enrollment through six study visits over a period of approximately 12 weeks

  2. Changes in osteocalcin levels

    Secondary outcome assesing changes in the bone turnover marker osteocalcin

    Time frame: From enrollment through six study visits over a period of approximately 12 weeks

  3. Changes in immune respons (Treg/Th17 cell ratio)

    Secondary outcome assesing changes in the immune cell composition (Treg/Th17 cell ratio)

    Time frame: From enrollment through six study visits over a period of approximately 12 weeks

  4. Changes in the incretin hormone GLP-2

    Secondary outcome assesing changes in levels of GLP-2

    Time frame: From enrollment through six study visits over a period of approximately 12 weeks

07

Study locations

1 site
  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital
    Aarhus N, 8200, Denmark
08

References and documents

Publications

  • Giuntini EB, Sarda FAH, de Menezes EW. The Effects of Soluble Dietary Fibers on Glycemic Response: An Overview and Futures Perspectives. Foods. 2022 Dec 6;11(23):3934. doi: 10.3390/foods11233934. PubMed 36496742 ↗
  • Weber AM, Pascale N, Gu F, Ryan EP, Respondek F. Nutrition and health effects of pectin: A systematic scoping review of human intervention studies. Nutr Res Rev. 2025 Jun;38(1):306-323. doi: 10.1017/S0954422424000180. Epub 2024 Sep 26. PubMed 39324277 ↗
  • Sanggaard KM, Holst JJ, Rehfeld JF, Sandstrom B, Raben A, Tholstrup T. Different effects of whole milk and a fermented milk with the same fat and lactose content on gastric emptying and postprandial lipaemia, but not on glycaemic response and appetite. Br J Nutr. 2004 Sep;92(3):447-59. doi: 10.1079/bjn20041219. PubMed 15469648 ↗
  • Menard O, Famelart MH, Deglaire A, Le Gouar Y, Guerin S, Malbert CH, Dupont D. Gastric Emptying and Dynamic In Vitro Digestion of Drinkable Yogurts: Effect of Viscosity and Composition. Nutrients. 2018 Sep 14;10(9):1308. doi: 10.3390/nu10091308. PubMed 30223532 ↗
  • Berry SD, McLean RR, Hannan MT, Cupples LA, Kiel DP. Changes in bone mineral density may predict the risk of fracture differently in older adults according to fall history. J Am Geriatr Soc. 2014 Dec;62(12):2345-9. doi: 10.1111/jgs.13127. Epub 2014 Nov 29. PubMed 25438807 ↗
  • Sayon-Orea C, Martinez-Gonzalez MA, Ruiz-Canela M, Bes-Rastrollo M. Associations between Yogurt Consumption and Weight Gain and Risk of Obesity and Metabolic Syndrome: A Systematic Review. Adv Nutr. 2017 Jan 17;8(1):146S-154S. doi: 10.3945/an.115.011536. Print 2017 Jan. PubMed 28096138 ↗
  • Miller KC. Plasma potassium concentration and content changes after banana ingestion in exercised men. J Athl Train. 2012 Nov-Dec;47(6):648-54. doi: 10.4085/1062-6050-47.6.05. PubMed 23182013 ↗
  • Keszthelyi D, Knol D, Troost FJ, van Avesaat M, Foltz M, Masclee AA. Time of ingestion relative to meal intake determines gastrointestinal responses to a plant sterol-containing yoghurt drink. Eur J Nutr. 2013 Jun;52(4):1417-20. doi: 10.1007/s00394-012-0440-3. Epub 2012 Aug 23. PubMed 22915051 ↗
  • Starup-Linde J, Ornstrup MJ, Kjaer TN, Lykkeboe S, Handberg A, Gregersen S, Harslof T, Pedersen SB, Vestergaard P, Langdahl BL. Bone Density and Structure in Overweight Men With and Without Diabetes. Front Endocrinol (Lausanne). 2022 Mar 10;13:837084. doi: 10.3389/fendo.2022.837084. eCollection 2022. PubMed 35360074 ↗
  • Fuglsang-Nielsen R, Rakvaag E, Vestergaard P, Hermansen K, Gregersen S, Starup-Linde J. The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity - A Post Hoc Analysis. Front Endocrinol (Lausanne). 2022 Mar 29;13:832897. doi: 10.3389/fendo.2022.832897. eCollection 2022. PubMed 35422766 ↗
  • Veldhuis-Vlug AG, Rosen CJ. Mechanisms of marrow adiposity and its implications for skeletal health. Metabolism. 2017 Feb;67:106-114. doi: 10.1016/j.metabol.2016.11.013. Epub 2016 Nov 27. PubMed 28081773 ↗
  • Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst JJ, Hartmann B, Vestergaard P, Gregersen S. Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017 Apr;97:261-266. doi: 10.1016/j.bone.2017.01.027. Epub 2017 Jan 23. PubMed 28126633 ↗
  • Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009 Nov;45(5):833-42. doi: 10.1016/j.bone.2009.07.008. Epub 2009 Jul 22. PubMed 19631303 ↗
  • Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 2002 Jan;30(1):307-13. doi: 10.1016/s8756-3282(01)00662-7. PubMed 11792602 ↗
  • Bjornshave A, Lykkeboe S, Hartmann B, Holst JJ, Hermansen K, Starup-Linde J. Effects of a whey protein pre-meal on bone turnover in participants with and without type 2 diabetes-A post hoc analysis of a randomised, controlled, crossover trial. Diabet Med. 2021 Jun;38(6):e14471. doi: 10.1111/dme.14471. Epub 2020 Dec 13. PubMed 33259643 ↗
  • Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011 Aug;49(8):1271-1274. doi: 10.1515/CCLM.2011.602. Epub 2011 May 24. PubMed 21605012 ↗
  • Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa048. doi: 10.1210/clinem/dgaa048. PubMed 32068863 ↗
  • Hansen L, Mathiesen AS, Vestergaard P, Ehlers LH, Petersen KD. A health economic analysis of osteoporotic fractures: who carries the burden? Arch Osteoporos. 2013;8(1):126. doi: 10.1007/s11657-013-0126-3. Epub 2013 Feb 19. PubMed 23420317 ↗
  • Guzman Ibarra M, Ablanedo Aguirre J, Armijo Delgadillo R, Garcia Ruiz Esparza M. [Prevalence of osteopenia and osteoporosis assessed by densitometry in postmenopausal women]. Ginecol Obstet Mex. 2003 May;71:225-32. Spanish. PubMed 12908337 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 16 months is below that.

Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 9, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Apr 2027was Oct 2026
CompletionEst.
May 2027was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Nov 4, 2026
Primary completion
Oct 2026→Apr 2027
Nov 4, 2026
Study completion
Oct 2026→May 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Oct 2026→Apr 2027
    Study completion Oct 2026→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07056322
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Dec 1, 2025
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jakob S Linde, Medical Doctor, MD, PhD
principal investigator · Department of Endocrinology and Internal Medicine, Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: cow's milk · Banana

Start the discussion